Skip to main content
. 2016 Nov 30;90:283–289. doi: 10.1016/j.bios.2016.11.068

Fig. 3.

Fig. 3

a) Dose-inhibition curves of sitagliptinon (0–0.5 μM) on GP-BAN hydrolysis in both human plasma and DPP-IV. IC50 =13.00 nM, 16.59 nM, respectively. b) Dose-inhibition curves of vildagliptin (0–2.5 μM) on GP-BAN hydrolysis in both human plasma and DPP-IV. IC50 =58.65 nM, 85.12 nM, respectively.